Login to Your Account

Clinic Roundup

Wednesday, June 19, 2013

• Adamas Pharmaceuticals Inc., of Emeryville, Calif., reported that the company's Phase II/III EASED (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia) trial of ADS-5102 (Nurelin, amantadine HCl extended release) met the primary endpoint, defined as the reduction in levodopa-induced dyskinesia in Parkinson's patients over eight weeks compared to placebo, as measured by the Unified Dyskinesia Rating Scale.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription